医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ABEC 4,000 Liter Single-Use Bioreactor to Expand Emergent BioSolutions Manufacturing Capability

2017年10月24日 PM10:32
このエントリーをはてなブックマークに追加


 

BETHLEHEM, Pa.

ABEC, a global provider of integrated solutions and services for biopharmaceutical manufacturing, today announced that Emergent BioSolutions will equip their Baltimore, Maryland bulk manufacturing facility (Bayview), designated a Center for Innovation in Advanced Development and Manufacturing (CIADM), with an ABEC 4,000L CSR bioreactor. The system will be custom designed to Emergent’s process needs, operational requirements, and facility constraints, and will greatly expand cell culture capacity at the Bayview site.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005257/en/

ABEC Custom Single Run (CSR®) Scalable Single-Use Solutions (Photo: Business Wire)

ABEC Custom Single Run (CSR®) Scalable Single-Use Solutions (Photo: Business Wire)

The 4,000L CSR is the largest single use bioreactor size available in the industry by a factor of two, resulting in approximately twice the productivity per floor space and lower cost of goods for cell culture-based biopharmaceuticals. The system can also deliver performance comparable to stainless steel systems and can be fully customized for different products, resulting in higher cell culture productivity and faster process transfer and scale-up.

Scott Battist, Emergent BioSolutions Vice President and General Manager of the Bayview site said, “The CIADM is designed to be a flexible, multi-product facility that cost-effectively addresses the diverse needs of our customers. ABEC’s CSR enables us to fully realize the benefits of single use technology by improving flexibility while leveraging economies of scale.”

“Emergent has been an ABEC customer for many years,” said Scott Pickering, ABEC President and CEO. “We are pleased that Emergent has chosen ABEC’s CSR technology to be part of their next-generation manufacturing strategy, and we look forward to continuing this long-term partnership.”

About ABEC

Since 1974, ABEC has been a leader in delivering integrated process solutions and services for manufacturing in the biopharmaceutical industry. A majority of the world’s pharmaceutical and biotech companies are ABEC customers with many of today’s leading therapies manufactured by processes and equipment engineered, manufactured, installed and serviced by ABEC. ABEC’s unique value is based on long experience, complete in-house capabilities, a custom, flexible approach, and long-term credibility. Whether adding capacity or improving existing facilities ABEC’s turn-key solutions and support services reduce overall cost and time to market while delivering maximum productivity. Visit: www.abec.com, www.abecsingleuse.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171024005257/en/

CONTACT

ABEC
Media Contact:
Susan Cooper Curcio, Director of Marketing
+1
610-861-4666
scurcio@abec.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • SCIEX and NUS Faculty of Science Announce Plans to Launch New Training Centre for Proteomics and Mass Spectrometry Across Asia Pacific
  • Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia
  • Preceptis Medical宣布面向中国的B轮融资和全球增长战略
  • オクタファルマ、開発途上国の血友病患者を治療するために当社のNuwiq製剤3050万国際単位を寄付
  • Octapharma捐赠3050万国际单位该公司药品 Nuwiq以治疗发展中国家的血友病患者